Terms: = Brain cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Clinical Outcome
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Features of Resected Melanoma brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
3. Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.
Lupi I; Manetti L; Caturegli P; Menicagli M; Cosottini M; Iannelli A; Acerbi G; Bevilacqua G; Bogazzi F; Martino E
J Clin Endocrinol Metab; 2010 Jan; 95(1):289-96. PubMed ID: 19875479
[TBL] [Abstract] [Full Text] [Related]
4. BAALC, a novel marker of human hematopoietic progenitor cells.
Baldus CD; Tanner SM; Kusewitt DF; Liyanarachchi S; Choi C; Caligiuri MA; Bloomfield CD; de la Chapelle A
Exp Hematol; 2003 Nov; 31(11):1051-6. PubMed ID: 14585369
[TBL] [Abstract] [Full Text] [Related]
